Dr. Alexandra Zaleta discussed the impact of administrative delays and insurance red tape experienced by patients with ...

My cancer journey taught me that nothing is certain; however, with support, humor and acceptance, we can weather the ups and ...

Prehabilitation and early screening, including BIS, can ease recovery, reduce side effects and help manage lymphedema after ...

Valarie Traynham sat down for an interview in CURE in which she discussed adjusting to life after cancer, detailing her ‘new normal.’ ...

A cancer thriver reflects on the emotional toll, survivorship, advocacy and support networks they wish they’d known at ...

It took years to understand why my mastectomy site looked different. Knowing I healed correctly for my procedure helped me ...

In a phase 2 study, 52% of patients treated with Bria-IMT plus a checkpoint inhibitor for metastatic breast cancer were alive at one year.

Key Takeaways The narrative draws parallels between childhood fears and the persistent anxiety of cancer recurrence, emphasizing the psychological impact on survivors. Despite being cancer-free for ...

Key Takeaways Cancer research funding involves federal, state, and private resources, with NIH and NCI as major contributors. Proposed 2026 budget cuts to NIH threaten progress in cancer research and ...

Key Takeaways Tumor-infiltrating lymphocyte (TIL) therapy offers a novel approach for advanced melanoma, leveraging the patient's immune system for treatment-resistant cases. The FDA approved a ...

CURE connects oncology patients, survivors, and caregivers with expert guidance, cancer updates, treatment education, and clinical trial access.

Final results indicate that three out of five patients treated with leronlimab had at least a partial response, including one patient with a complete response who remains alive five years later, for ...